US obesity rate down amid increase in weight loss drugs

A new Gallup survey shows that the US obesity rate has fallen to 37%, down from nearly 40% in 2022, largely due to the growing use of weight-loss drugs like Ozempic, Wegovy, Zepbound, and Mounjaro.

Approved for obesity treatment in 2021, GLP-1 drugs suppress appetite and slow digestion, marking a major breakthrough in tackling obesity and diabetes. The poll found that the share of Americans taking GLP-1s for weight loss has more than doubled—from 5.8% in early 2024 to 12.4% in 2025.

The biggest declines in obesity have occurred among adults aged 40–64, particularly those 50–64, where rates dropped 5 points to 42.8%. They are also the highest users, accounting for 17%.

Usage is also higher among women (15.2%) than men (9.7%).

However, access remains a concern as many private insurers plan to end coverage next year, potentially forcing patients to pay about $500 per month out of pocket. 

The global obesity drug market could hit $150 billion by 2030.